Table 1 Clinical trials involving siRNA therapeutics for ocular diseases

Silence Therapeutics/ Quark/Pfizer

PF-655 (formerly REDD14NP and RTP801i)

RTP801/ DNA-damage- inducible transcript 4 gene (DDIT4)

Naked siRNA

AMD

Intravitreal injection

Phase II – completed

(Pfizer 2011a[50]; Quark Pharmaceuticals 2011a[52]);[55]

Silence Therapeutics/ Quark/Pfizer

PF-655 (formerly REDD14NP and RTP801i)

RTP801/DNA- damage-inducible transcript 4 gene (DDIT4)

Naked siRNA

DME

Intravitreal injection

Phase II – terminated

(Pfizer 2011b[51]; Quark Pharmaceuticals 2011a[52])

Allergan/Sirna

AGN211745 (Sirna-027)

VEGFR1

Naked siRNA

AMD

Intravitreal injection

Phase II- terminated

(Allergan 2008[46]; Allergan 2009)[47];[48]

Opko Health

Bevasiranib

VEGF

Naked siRNA

Wet AMD

Intravitreal injection

Phase III-terminated

(OpkoHealth 2011[49])

Sylentis

SYL040012

ADRB2

Naked siRNA

Glaucoma, Ocular hypertension

Topical

Phase I-completed

(Sylentis 2010[54])

Quark

QPI-1007

Caspase 2

Naked siRNA

Non-arteritic ischemic optic neuropathy (NAION), Chronic optic nerve atropy, Glaucoma

Intravitreal injection

Phase I – on going

(Quark Pharmaceuticals 2011b[53])